

The Board:

1. *Acknowledges the original grant duration, as expressed by either the implementation or budgeted period, of Nigeria malaria and its constituent grants, as described in GF/B36/ER09, was shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DPO9 when approved by the Board in January 2015 under GF/B32/EDP05;*
2. *Approves the redistribution of funding available to Nigeria malaria, and its constituent grants, under the Board's approval of additional funding in January 2015 (GF/B32/EDP05) as well as the additional implementation period recommended for Nigeria malaria, and its constituent grants, as listed in Tables 1a and 1b of GF/B36/ER09 and described in GF/B36/ER09, paragraph 1.4;*
3. *Acknowledges Nigeria malaria's constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;*
4. *Affirms the funding available for Nigeria malaria under GF/B32/EDP05 and this decision (a) remains the upper-ceiling amount that may be available for the relevant implementation period of each constituent grant, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and*
5. *Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.*

This decision does not have material budgetary implications for the 2017 Operating Expenses Budget.

Table 1a: Secretariat's Funding Recommendation on New Grant Using Approved Funding from the 2014-2016 Allocation

N	Applicant	Disease component	Proposed Principal Recipient (Grant Name)	Currency	Grant end date	Total Grant Budget	Sources		Recommended Total Incremental Funding	Incentive Funding included in Total Incremental Funding	Unfunded Quality Demand	Domestic Commitment
							Existing Funding	Recommended Incremental Funding				
1	Nigeria	Malaria	NGA-M-CRS	US\$	31-Dec-17	103,066,704	103,066,704 ¹	0	0	0	43,041,512	340 million

Table 1b: Secretariat's Funding Recommendation on Shortened Grant

N	Applicant	Disease Component	Grant Name	Currency	Period of Extension (Months)	Previously Approved Grant Budget	Revised Budget for Board Approval	Original Existing Funding	Additional Existing Funding	Incremental Funding Already Approved	Additional Incremental Funding for Board Approval	Total Additional Incremental Funding for Board Approval	Revised Unfunded Quality Demand
1	Nigeria	Malaria	NGA-M-NMEP	US\$	12	308,577,343	255,614,212	20,400,470	0	288,176,873	0	0	43,041,512

¹ Represents reprogramming of existing funds within the current NGA-M-NMEP and NGA-M-SFH grants and does not increase the total program budget previously approved by the Board for Nigeria Malaria (GF/B32/EDPo5)